Frelin C, Guedin D
Institut de Pharmacologie Moléculaire et Cellulaire de CNRS, Université de Nice-Sophia Antipolis, Valbonne, France.
Cardiovasc Res. 1994 Nov;28(11):1613-22. doi: 10.1093/cvr/28.11.1613.
Physiological and pathophysiological roles of endothelins are still unclear. One reason is that circulating endothelin levels in normal and pathological states are much lower than the concentrations necessary to elicit contractions in vitro. It is usually assumed that endothelin accumulates in diseased tissues and that, because of its degradation, only a small fraction of it reaches the systemic circulation. Such a hypothesis does not fit with recent observations showing that low circulating endothelin levels may be active. We show here that most of the current inferences about the actions of endothelin assume that the peptide acts in the vessel wall under conditions known as non-stoichiometric binding conditions, that is, under conditions in which the receptor concentration in tissues ([Ro]) is smaller than the equilibrium dissociation constant of endothelin receptor complexes (Kd). Under stoichiometric binding conditions (defined by the condition [Ro] > Kd), most ligand molecules are bound to receptors and cannot be present in a free form. Estimates of [Ro] and Kd from the literature suggests that in vivo endothelin probably binds stoichiometrically to its receptors. Under this condition, most of tissue endothelin is probably bound to receptors. It is therefore suggested that plasma endothelin levels are low probably because tissue free endothelin levels are low, and this is not inconsistent with the presence of high tissue levels of active (that is, bound) endothelin. When the topology of the vessels with respect to the site of production (or of delivery) of endothelin is considered, stoichiometric binding may also account for the higher sensitivity to Et-1 of in vivo preparations. It also suggests that autocrine and paracrine actions of Et-1 are favoured at low and high secretory rates respectively, thus providing an explanation for the dual (vasodilator and vasoconstricting) actions of endothelin. Finally, the stoichiometric binding model predicts that functional receptors also act as clearance receptors and provides an explanation for the observation that antagonists of endothelin receptors are also clearance antagonists.
内皮素的生理和病理生理作用仍不清楚。一个原因是正常和病理状态下循环内皮素水平远低于体外引发收缩所需的浓度。通常认为内皮素在患病组织中蓄积,并且由于其降解,只有一小部分进入体循环。这样的假设与最近显示低循环内皮素水平可能具有活性的观察结果不符。我们在此表明,目前关于内皮素作用的大多数推断假定该肽在称为非化学计量结合条件下的血管壁中起作用,即在组织中受体浓度([Ro])小于内皮素受体复合物平衡解离常数(Kd)的条件下。在化学计量结合条件下(由[Ro]> Kd条件定义),大多数配体分子与受体结合,不能以游离形式存在。从文献中对[Ro]和Kd的估计表明,体内内皮素可能与其受体化学计量结合。在这种条件下,大多数组织内皮素可能与受体结合。因此有人提出,血浆内皮素水平低可能是因为组织中游离内皮素水平低,这与组织中高活性(即结合)内皮素的存在并不矛盾。当考虑血管相对于内皮素产生(或递送)部位的拓扑结构时,化学计量结合也可以解释体内制剂对Et-1的更高敏感性。这也表明Et-1的自分泌和旁分泌作用分别在低分泌率和高分泌率时更有利,从而为内皮素双重(血管舒张和血管收缩)作用提供了解释。最后,化学计量结合模型预测功能性受体也作为清除受体,并为内皮素受体拮抗剂也是清除拮抗剂的观察结果提供了解释。